ライフサイエンスコーパス: recurrent breast cancer

1 as a very low detection rate for nonpalpable recurrent breast cancer.

2 whole population of CTCs in 19 patients with recurrent breast cancer.

3 Seventeen patients (36.2%) developed recurrent breast cancer.

4 rt, and the patient was later proven to have recurrent breast cancer.

5 )F-FDG PET/CT scan findings in patients with recurrent breast cancer.

6 powerful approach for the early detection of recurrent breast cancer.

7 Costs of PMRT ($11,600) and recurrent breast cancer ($4,250 to 16,200/year) were est

8 or germline BRCA1/2-associated metastatic or recurrent breast cancer, an Eastern Cooperative Oncology

9 he serial samples were from 20 patients with recurrent breast cancer, and 141 samples were from 36 pa

10 supplemental, and total vitamin D intake and recurrent breast cancer, and a nested case-control study

11 Women with recurrent breast cancer are in need of programs to assis

12 Recurrent breast cancers arise from the pool of dissemin

13 se of this study was to quantify the risk of recurrent breast cancer associated with HRT among breast

14 cancer events: 14 patients developed new or recurrent breast cancer at a median time of 139.5 months

15 te a prediction model for early detection of recurrent breast cancer based on metabolic profiles.

16 uant BR RIA can be used as an aid to predict recurrent breast cancer in patients with stage II and II

17 sment of both palpable and clinically occult recurrent breast cancers in autogenous myocutaneous flap

18 ly advanced breast cancer and local-regional recurrent breast cancer is preferably performed with PET

19 Recurrent breast cancer is typically an incurable diseas

20 Detection of a new or recurrent breast cancer lesion relies on physical examin

21 egative histology; or confirmed diagnosis of recurrent breast cancer of any histology with known germ

22 mline BRCA mutations; confirmed diagnosis of recurrent breast cancer of triple-negative histology; or

23 Recurrent breast cancers often develop resistance to sta

24 08 consecutive patients with known/suspected recurrent breast cancer on [(18)F]FDG-PET/CT, characteri

25 nformation is available about the effects of recurrent breast cancer on the quality of life of women

26 on the development of a monitoring test for recurrent breast cancer, using metabolite-profiling meth

27 The detection rate for nonpalpable recurrent breast cancer was 0% (exact 95% confidence int

28 rogesterone receptor-positive, metastatic or recurrent breast cancer were enrolled in this prospectiv

29 standard deviation]) with newly diagnosed or recurrent breast cancer were recruited between November

30 All patients with recurrent breast cancer who are candidates for PARP inhi

31 erous transformation, as well as invasive or recurrent breast cancer, with dual-specificity radiohybr